



Unparalleled Contributions of 18F-FDG-PET Imaging to Medicine Over the Past Four Decades

Abass Alavi, M.D.

M.D.(Hon), Ph.D.(Hon), D.Sc.(Hon)

**Perelman School of Medicine, University of
Pennsylvania, Philadelphia, Pennsylvania**



How did this journey
begin and where is
it heading?




Fig. 1




Fig. 8








Fig. 9



^{14}C -deoxyglucose autoradiography




^{14}C -deoxyglucose autoradiography



Concept of Fluorodeoxyglucose (FDG)



**Alavi, Kuhl, Reivich
(University of Pennsylvania)**




**Wolf, Ido, Fowler
(Brookhaven National Laboratory)**

December 1973

[¹⁸F] FDG – the Molecule of the Century



I Uptake and Metabolism




Blood


Cell

The First Brain FDG Image 1976






*The first whole body human FDG scan was performed by
Abass Alavi
in August 1976 at University of Pennsylvania by employing a
conventional rectilinear machine as the only option at the time.*




Relative Sensitivity of Molecular Imaging Modalities

Sensitivity



Modality	Agents	H	R	Primary uses	Examples
FMT	fluorescent proteins		X	gene expression, tagging superficial structures	GFP, RFP, NIRF probes
BLI	luciferin		X	gene expression, therapeutic monitoring	fLuc rLuc
SPECT	^{99m}Tc , $^{123/5}\text{I}$, ^{111}In	X	X	site-selectivity, protein labeling	^{99m}Tc -annexin V, ^{123}I -A85380
PET	^{11}C , ^{18}F , ^{124}I , $^{64/62/60}\text{Cu}$	X	X	site-selectivity, gene expression, drug development	^{11}C -RAC, ^{124}I -FIAU, ^{64}Cu -ATSM
spectroscopy	endogenous metabolites	X	X	CNS, prostate, heart, breast	NAA, Cr, Cho, Glx, ml, ^{31}P
contrast agents	Gd, Mn, FeO		X	cell trafficking, enzymatic activation	poly-L-lysine, dendrimers, MION
contrast agents	perfluorinated microbubbles		X	drug-delivery, gene transfection	human albumin (Optison)



Integrated PET-CT Systems



Siemens



GE




Philips

Current and Potential Indications for FDG-PET Imaging



- **CNS Disorders (AD, Seizures disorders)**
- **Cancer**
- **Infection**
- **Inflammation**
- **Myocardial Viability**
- **Atherosclerosis**
- **Muscle Dysfunction**
- **Clot detection**







Normal Variation and Effects of Aging on Organ Function and Structure as Demonstrated by Modern Imaging Modalities



Abass Alavi, M.D.



M.D.(Hon),Ph.D.(Hon), D.Sc.(Hon)


**University of Pennsylvania School of
Medicine**





Correlation between age and whole brain metabolic rate (age range: 18– 85 years).









- **CANCER DIAGNOSIS**




58 yrs old female with Palpable mass in Right Breast




- **CANCER SATAGING**







Staging widespread melanoma



- **ASSESSING RESPONSE TO THERAPY**


Early Assessment for Response



STAGING




AFTER 2 CYCLES
OF VNCOP-B




CT BASED PRACTICE

CT




Therapy "A"



2-3 months




Therapy "B"



Therapy "A"




Therapy "B"






- **PET BASED PRACTICE**

PET/CT



24 - 48 hours

Therapy "A"




Therapy "B"



Therapy "A"






Therapy "B"




Therapy "B"




6 months



- **DETECTION OF RECURRENCE**









MRI T1Gd




90 min

473 min





The Role of PET-CT/MRI Co- registration in Radiation Therapy







FDG-PET for the Diagnosis of Infections and inflammation



Chronic Osteomyelitis




Sinus Track Connecting Soft-Tissue Abscess With Bone



SPGR = spoiled gradient.

FDG-PET/CT in Diabetic Foot








FDG-PET Image- vasculitis is confirmed.

[Otsuka H, Morita N, Yamashita K, Nishitani H.](#)
FDG-PET/CT for diagnosis and follow-up of vasculitis.
J Med Invest. 2007 Aug;54(3-4):345-9.

Inflammatory Bowel Disease



Atherosclerosis



First Hour




Second Hour




Third Hour

FDG PET CT – Inflammation in Aorta

a




b




FDG PET + CT

24-year old male



FDG PET CT

60-year old female





FDG PET CT



61-year-old caucasian male



- Adipose, recent pneumonia and gout, bedridden for weeks
- 2 day history of swelling and tenderness of right lower extremity
- D-dimer 19 mg/L (ref. < 0,5 mg/L), Wells' score 4
- CUS: RLE DVT (mid-femoral to distal calf)
- PET/CT: Positive for RLE DVT, otherwise normal





Differential dynamics of FDG between malignant and inflammatory cells





[¹⁸F] FDG – the Molecule of the Century

I Uptake and Metabolism






Time 1






Time 2

Retention Index: SUVmean





P-Value = 0.004

Lung Ca, additional pleural and Lymph nodes mets




1 hour




3 hours

**FIRST TIME
POINT (Early)**




**SECOND TIME
POINT (Delay)**




**DUAL TIME IMAGING IN
MESOTHELIOMA**


Early Image Max SUV= 3.5

Delayed Image Max SUV= 4.8






RESULTS




Table


Histopathology	Avg. SUVmax 1	Avg. SUVmax 2	Avg. Percent SUV Change (%)
Malignant Mesothelioma (n = 28)	4.6 ±2.5	5.3 ±2.8	14.0 ±12.4
Benign Pleural Disease (n = 4)	1.5 ±0.2	1.3±0.2	-10.5 ±21.6 <small>P ≤ 0.002</small>




45-Minutes




3-hour



Temporal profile of FDG uptake in Lung Cancer





Assessing Tumor Biology and Forecasting Prognosis

Assessment of Tumor Biology in Breast Cancer


Based on Time Course of FDG in the Primary Site





	Primary Breast lesions in patients without Axillary or Distant Metastasis	Primary Breast lesions in patients with Axillary Metastasis	Primary Breast lesions in Patients with Distant Metastasis	p
SUVmax1	2.9 ± 2.7	4.8 ± 3.9	7.7 ± 6.2	0.01*
SUVmax2	3.4 ± 2.4	5.3 ± 4.5	8.9 ± 7.1	0.01*
%ΔSUVmax	4.5 ± 4.2%	9.4 ± 12.8%	15.7 ± 10.8%	>0.05




SUVs in the primary lesions were highest in Gp II (those with both axillary and distant metastases), followed by Gp I (those with only metastatic axillary adenopathy) and Gp III (patients without any metastasis)

Global metabolic activity (GMA)





DLBCL




$V = 306.25 \text{ cc}$
 $MVP = 5175.79 \text{ SUV cc}$
 $cMVP = 9333.10 \text{ SUV cc}$
 $\Delta MVP = 80.3\%$

Life Beyond FDG



- **FLT (DNA Synthesis)**
- **^{60}Cu -ATSM, ^{18}F -EF5, ^{18}F -FMISO**
- **(Assessment for hypoxia)**
- **FIAU, FHBG, FHPG (Gene therapy)**
- **^{11}C -Acetate (Slow growing tumors)**
- **^{18}F or ^{11}C -labeled Choline**
- **(Slow growing tumors)**
- **^{18}F -Fluoride (Bone imaging)**



Imaging of Non-small Cell Lung Cancer




AF Shields, JR Grierson, BM Dohmen, H-J Machulla et al.
Nature Med 4:1334, 1998

90 Minutes


MRI Post-GAD
Sequence





^{18}F -EF5 PET





Comparison of Average SUVmean-asc




- The mean \pm SD of SUVmean-arch for healthy and non-healthy subjects were 0.83 ± 0.20 and 1.02 ± 0.29 , respectively; and this difference was significant (P value <0.001). The spearman CC of healthy and non-healthy subjects were 0.37 (P=0.001) and 0.67 (P <0.001), respectively. The trend-lines for both groups are shown below.





Global cardiac ^{18}F -NaF uptake



A



B



The CT, PET, and PET/CT images shown above from two normal subjects, a 28 year-old male (A) and a 64 year-old female (B). The femoral neck activity is anatomically defined with the medial boundaries based on the epiphyseal line and lateral boundaries by the intertrochanteric ridge. Based on this delineation, quantitative metrics were generated in both subjects. Total calcium metabolism ($TCM = SUV_{mean} * \text{metabolically active volume}$) in patient (A) was 6715.79 while TCM in patient (B) was 2587.44.






FIGURE 5. Heart uptake and DAR from control and apoE ^{-/-} mice. (A) Mean heart uptake obtained after intravenous administration of [¹²⁵I]IONPs into healthy and atherosclerotic mice (*n*=4). (B) Mean heart-to-blood ratios obtained after intravenous administration of [¹²⁵I]IONPs into healthy and atherosclerotic mice (*n*=4). (C) DAR obtained from heart of healthy and atherosclerotic mice, respectively, at 72 h post-injection of [¹²⁵I]IONPs (20 μCi, 0.8 mg Fe/kg).

Philips Ingenuity TF PET/MR

Sequential PET and MR imaging



CE Mark in Europe
FDA 510(k) clearance in US




<http://multivu.prnewswire.com/mnr/philips/4819>

Potential Future Applications



**Neurological Disorders
and Diseases**






**Cardiovascular
Disorders and Diseases**



**Musculoskeletal
Disorders and Diseases**

Fusion Imaging of PET and MRI Metabolic Function in In-vivo Human Brainstem



Raphe-Magnus, Obscurus, Pallidus

Raphe Pontis

This text block contains two labels for the raphe nuclei: 'Raphe-Magnus, Obscurus, Pallidus' and 'Raphe Pontis'. Red arrows from these labels point to the corresponding structures in the 7.0T MRI image.


PET-MRI Fusion

This text label is positioned below the PET-MRI fusion image, indicating the combined visualization of the anatomical MRI and the metabolic PET data.


Anatomy Obtained by 7.0T MRI

SUVr of Glucose Metabolism
By Fusion PET-MRI

FDG PET/CT in Cardiac Sarcoidosis



Cardiac MRI




FDG PET/MRI

Images in a 51-year-old man with history of cardiac dysrhythmias and sarcoidosis who underwent evaluation for cardiac involvement.

Axial software-fused FDG PET/MR image of heart demonstrates heterogeneously increased FDG uptake (arrows) in left ventricular myocardium.

FDG-PET/CT in Diabetic Foot




Imaging Plaques and Tangles in Patients with Cognitive Impairment





Normal vs. Alzheimer's Diseased Brain

Normal






Alzheimer's





PiB





BRAAK AND BRAAK

CORTICAL DESTRUCTION IN ALZHEIMER'S DISEASE


Neurobiology of Aging, Vol. 18, No. 4, pp 351-357, 1997
Copyright © 1997 Elsevier Science Inc.
Printed in the USA. All rights reserved
0197-4580/97 \$17.00 + .00


FDG



Imaging (PET)


Pathology






- FDG-PET-CT Imaging has had a substantial impact on research and on the day to day practice of medicine. This has resulted in minimizing pain and suffering for millions of patients with serious diseases/disorders and in reducing cost of health care worldwide.

Thank You





Thank you